PD
ARQT icon

Point72 (DIFC)’s Arcutis Biotherapeutics ARQT Stock Holding History

Point72 (DIFC)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$28.6K Buy
+1,515
New +$23.9K ﹤0.01% 824
2025
Q2 		– Sell
-2,149
Closed -$33.6K – 1541
2025
Q1 		$33.6K Sell
2,149
-3,134
-59% -$44.2K ﹤0.01% 1276
2024
Q4 		$73.6K Buy
5,283
+2,614
+98% +$28.6K ﹤0.01% 1059
2024
Q3 		$24.8K Buy
+2,669
New +$26.3K ﹤0.01% 1182

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 (DIFC)'s ARQT Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2025: 1,515 shares worth $28.6K. The stake represents ﹤0.01% of the portfolio and ranks #824 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in ARQT as recently as Q1 2025.

Point72 (DIFC) first reported a position in ARQT in Q3 2024 and has held it in 4 quarters since. The position peaked at $73.6K in Q4 2024. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Point72 (DIFC) held 1,515 shares of Arcutis Biotherapeutics worth $28.6K as of Q3 2025.
  • Arcutis Biotherapeutics was a new Point72 (DIFC) position in Q3 2025.
  • Arcutis Biotherapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #824 holding.
  • Point72 (DIFC) first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • Point72 (DIFC)'s Arcutis Biotherapeutics position peaked at $73.6K in Q4 2024.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.